A double blind, sequential, ascending single dose, placebo-controlled safety, tolerability, and pharmacokinetic and pharmacodynamic study of TC-2216 [Targacept] in healthy young male volunteers

Trial Profile

A double blind, sequential, ascending single dose, placebo-controlled safety, tolerability, and pharmacokinetic and pharmacodynamic study of TC-2216 [Targacept] in healthy young male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2008

At a glance

  • Drugs TC 2216 (Primary)
  • Indications Anxiety disorders; Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Targacept
  • Most Recent Events

    • 17 Jul 2008 Status changed from recruiting to completed, from clinicaltrials.gov record.
    • 09 Nov 2007 Treatment has been well tolerated in all dose groups evaluated to date.
    • 09 Nov 2007 Status changed from initiated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top